Testing the drug NEO100 in people with high-grade meningioma

Official title: NEO100 and High-Grade Meningioma

Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.

The trial team last updated this record on July 16, 2026.

The short version

This study is testing a drug called NEO100 in people whose high-grade meningioma is still there, has grown, or has come back.

Read our full plain-language summary

What the trial team says

This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle until disease progression, death or patient withdraw from study for any reason, whichever occurs first.

From the trial's own listing on ClinicalTrials.gov.

Key facts

Registry number: NCT05023018
Stage of testing: Phase 2
Conditions studied: Residual, Progressive or Recurrent Grade II or III Meningioma

Where it is running

This trial lists 5 sites.

California
- University of Southern California (Los Angeles)
- Sutter Health Research Institute (San Francisco)
- Saint John Cancer Institute (Santa Monica)
Massachusetts
- Tufts Medical Center (Boston)
Texas
- Baylor Scott and White (Dallas)

How to use this

Talk to your care team first. They know your history and can tell you whether this trial is worth your time.

Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.

See the full listing on ClinicalTrials.gov

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.